RussianPatents.com

Fish (A61K35/60)

Bioregulatory complex possessing tissue-specific regenerative action, method for preparing it and method of treating cataract using it

Bioregulatory complex possessing tissue-specific regenerative action, method for preparing it and method of treating cataract using it

Invention refers to pharmaceutical industry, namely a bioregulatory complex possessing regenerative action. The bioregulatory complex possessing regenerative action prepared of gills of post-settlement Atlantic salmon (Salmo salar L.) activated for a prolonged life cycle with symbiotic pearl shell (Margaritifera margaritifera) alevins, containing peptides and oligosaccharides with certain physicochemical characteristics. A method for preparing a bioregulatory complex consisting the fact that the gills are prepared in the Atlantic salmon fished out after the settlement and placed into water or ethanol; the prepared gill extract is filtered; monoatomic aliphatic alcohol is added to the filtrate that is kept to deposit any foreign matters; the deposition is filtered off; the filtrate is evaporated dry, dissolved in water and cleaned in the specific environment. A method of treating early cataract.

Method for complex processing of fish raw material for obtaining hyaluronic acid and collagen

Method for complex processing of fish raw material for obtaining hyaluronic acid and collagen

Skins of pond fish are flushed with cold flushing water during 10-15 minutes. They are crushed to the size of 2-3 mm. Water extraction is performed at the temperature of 40-45°C during 40-50 minutes at the ratio of crushed skins to water, which is equal to 1:1 at periodic mixing. Then, they are filtered; liquid fraction is dried in a spraying drier at the drier outlet product temperature of 60-65°C during 15-25 minutes so that hyaluronic acid is obtained. Solid fraction is subject to bleaching during 12 hours with hydrogen peroxide-salt solution that is prepared by mixing of 1 l of 3% hydrogen peroxide and 20 g of sodium chloride. Treatment of bleached solid fraction is performed with 1.0-1.2% solution of sodium hydroxide during 24 hours at the temperature of 20-25°C with further neutralisation of the obtained mixture with 3% boric acid solution. Treatment of swollen solid fraction is performed with Pancreatin ferment preparation solution taken in the quantity of 0.5-0.6% to the weight of solid fraction during 1.5-2.0 hours at the temperature of 37-40°C. Flushing of solid fraction is performed with cold flushing water for removal of Pancreatin residues so that collagen is obtained. The obtained collagen, depending on the purpose, is supplied for drying in drying chambers with forced air circulation at the temperature of 18-20°C during 12 hours and storage in dry ventilated rooms at the temperature of not higher than 20°C during 24 months or frozen to the temperature of minus 18 - minus 20°C and stored at the temperature of minus 18 - minus 20°C during 24 months. The liquid fraction dried in the spraying chamber is stored at the temperature of 0-4°C during 12 months or dissolved in physiological buffer solution.

Method for preparing complex of biologically active substances of cod liver

Invention refers to medicine and veterinary science. What is presented is a method for preparing biologically active substances of cod (Gadidae) liver. For the purpose of preparing the biologically active substances, cod liver is homogenised; cut meat is processed with an extractant that is a mixture of vegetable oil and water in ratio of raw material: extractant 1:0.2-2. The processing is carried out at room temperature for 10 min to 1 h with mixing in a mixing machine at 50-200 rpm. Next, the ballast deposition is separated; macromolecular proteins are precipitated by treatment in an organic solvent. The solvent is specified in: 95% ethanol, acetone, acetonitrile, isopropanol, in the volumetric proportions of extractant-solvent 1:1-5. The treatment in the organic solvent is conducted at temperature -5 to +10°C. Thereafter, the suspension is settled at room temperature for 5-6 hours. The precipitation is separated by filtration to prepare an end product by drying the water residue.

Method for preparing katran oil

Invention refers to pharmaceutical industry, namely to a method for preparing fish oil. A method for preparing fish oil involving raw material grinding with distilled water added in weight ratio of the ground material to water 1:2, that is followed by homogenising, adding another portion of distilled water and mixing, phasing by settling; an oil fraction is gradually heated, centrifuged and filtered under certain conditions.

Biologically active complex possessing anti-allergic action

Biologically active complex possessing anti-allergic action

Invention refers to pharmaceutical industry and represents a complex of biologically active substance for treating allergic diseases of various genesis, characterised by the fact that it has been recovered from cod liver oil by gradual fractionation from ballast lipids by extraction in a two-phase oil and water extractant, centrifugation and ultrafiltration or diafiltration through a material with separation limit 25 kDa, and contains peptides 30-55%, amino acids 40-65%, carbohydrates 2-8%, micro and macroelements 2-13%.

Orally disintegrated composition containing polyunsaturated fatty acids and having no unpleasant odour or taste

Present invention refers to an orally disintegrated composition having no unpleasant odour or taste and used for blood lipid control, prevention or reduction of a risk of developing atherosclerotic changes, disorders or diseases. The above composition contains cod liver oil, perilla seed oil or polyunsaturated fatty acids (PUFA) and a disintegrant. The PUFA represent omega 3 fatty acids, omega 6 fatty acids, arachidonic acid, linoleic acid, alpha-linoleic acid, dihomo-gamma-linoleic acid, eicosapentaenoic acid, docosahexaenoic acid or a mixture thereof. The disintegrant represents solid dispersions containing mannitol, xylitol, microcrystalline cellulose, crospovidone and dibasic calcium phosphate.

Method of treating necrosis of hip bone head

Method of treating necrosis of hip bone head

Invention relates to medicine, namely to traumatology and orthopedics, and can be applied for treatment of osteonecrosis of hip bone head. For this purpose at the beginning partial selective section of hip joint muscles near places of their fastening to joint is carried out. After that, single-stage dosed destruction of affected part of extremity is realised to increase crack width and bring affected part of osteonecrosis from under the load. After that, proximal part of hip bone is rotated until section of osteonecrosis is matched with zone of front access. Then, from front access puncture of hip joint is performed. Then, medications, possessing osteochondroprotective and anti-inflammatory action, are introduced into joint surface into osteonecrosis section.

Method of performing anesthesia in experiment

Invention relates to field of medicine, in particular, to experimental anesthesiology and resuscitation science. Method is realised in experiment by introduction of protamine sulfate in dose 10 mg/kg of animal weight before introduction of narcotic medication such as ether, or ethanol, or droperidol, or aminasin, or sodium oxybutirate.

Method of treating endometritis in cows

Method of treating endometritis in cows

Invention relates to veterinary science. There are involved the intrauterine infusions of the ozonised emulsion 100.0 ml consisting of equal portions of cod liver oil and linseed infusion every 48 hours until clinical recovery is observed.

Method for preparing peptide complex of cod liver

Invention refers to medicine and veterinary science, namely a method for preparing a biologically active peptide complex of Gadidae fam. liver. The method involves grinding a raw material, extracting in mixed oil and water in proportions of raw material: extractant 1:5-1:30 at room temperature for 2-4 hours with agitation. Further, the end product is purified by treating in an organic solvent in relation of 1:0.5-2 followed by separation and drying of an aqueous residue. The raw material is presented by cod liver either fresh, frozen or dry, while the organic solvent is specified in a number of diethyl ester, ethyl acetate, butanol, chloroform.

Pharmaceutical composition possessing anti-inflammatory, immunotropic, antiallergic and wound healing action

Pharmaceutical composition possessing anti-inflammatory, immunotropic, antiallergic and wound healing action

Invention refers to chemical-pharmaceutical industry, medicine and veterinary science, particularly new drugs for inflammatory diseases of various geneses. What is presented is a pharmaceutical composition possessing anti-inflammatory, immunotropic, antiallergic and wound healing action which represents a solution for parenteral application and contains peptides associated with phospholipids prepared from cod liver, a wedding agent, sodium chloride, a preserving agent and water for injections. The composition may additionally contain ethanol in the amount of 1.0-15.0 wt %, an antioxidant in the amount of 0.01-0.5 wt % and a buffer in the amount of 0.1-5.0 wt %. The pharmaceutical composition has no side effects inherent in previously known drugs used for the same application.

Therapeutic and prophylactic toothpaste

Invention relates to creation of toothpaste for treatment of diseases of oral cavity mucosa and inflammatory diseases of periodontium tissues. Therapeutic and prophylactic toothpaste for treatment of inflammatory diseases of periodontium and oral cavity mucosa contains peptides associated with phospholipids, obtained from liver of Gadidae family with quantitative ratio, wt %: peptides 40-99 and phospholipids 1-60, as well as abrasive material, shape-forming thickening agent, water-retaining substance, cleaning and foam-generating component, preservative, dye, flavour and purified water in specified component ratio. Therapeutic and prophylactic toothpaste can additionally contain antioxidant, sweetener, plant extract, fluorides and/or desensitising agent. Application of toothpaste in short terms results in considerable improvement of state of periodontium and oral cavity tissues. In particular, fast elimination of inflammatory process, reduction of bleeding and painfulness of gums are observed.

High-molecular heparin composition with anticoagulant, anti-platelet, fibrinolytic and fibrin depolymerisation properties

Invention refers to medicine and pharmacology, and represents a composition of high-molecular heparin and fish oil Eiconol exhibiting anticoagulant, anti-platelet, fibrinolytic and fibrin depolimerisation properties for oral application differing by the fact that it additionally contains arginine in the following amounts of the ingredients at 90-120 IU of heparin activity: arginine 20-25 mg, Eiconol 1-1.1 ml.

Vascular ageing inhibitor and anti-ageing composition

Vascular ageing inhibitor and anti-ageing composition

Group of inventions refers to medicine, and concerns a vascular ageing inhibitor which contains as a basic ingredient collagen of low molecular weight approximately 3000 Da of fish skin prepared by enzymatic decomposition with using anacanthe or flatfish skin. The anti-ageing compositions contain the vascular ageing inhibitor in the granulated form.

High-molecular heparin composition with anticoagulant, anti-platelet, fibrinolytic and fibrin depolymerisation properties

Invention refers to medicine and pharmacology, and represents a composition of high-molecular heparin and fish oil Eiconol exhibiting properties for oral application differing by the fact that it additionally contains leucine in the following amounts of the ingredients at 90-120 IU of heparin activity: leucine - 0.56-0.58 mg, Eiconol -113-115 mg.

Cell and cell extract introduction for rejuvenation

Cell and cell extract introduction for rejuvenation

Invention refers to cosmetology and dermatology, and represents a method for preparing a local skin composition, involving: making fish roe available; and preparing a recovered water-soluble fraction of said fish roe differing by the fact that it contains messenger RNA and protein in the amount of 100 to 380 mg/ml where said fraction is prepared by destruction of said fish roe and decontamination by centrifugation of said lysed fish roe; and introducing said recovered water-soluble fraction of said fish roe into the composition of a cream, a gel, a spray, an emulsion, a solid, plastic material or a matrix, an ointment, a powder or a lotion for local application.

Method of therapeutic abortion in renal allograft recipient

Invention refers to medicine, namely obstetrics and transplantology, and concerns therapeutic abortion in renal graft recipients. That is ensured by introducing the following changes to the three-component immune suppression pattern. A dose of cyclosporine is corrected with regard to the blood concentration of this preparation, the therapeutic dose of cyclosporine is 95-120 ng/ml; a dose of methylprednisolone is increased to 15 mg/day three days prior to therapeutic abortion, and thereafter reduced within a month to initial values; the antibacterial therapy is prescribed for 3-5 days.

Method of prevention and treatment of thread of abortion in women with uterus myoma in accordance with new conception of its etiopathogenesis

Invention relates to medicine, namely to obstetrics and gynecology, and can be used for prevention and treatment of threat of abortion in women with uterus myoma. For this purpose patient is administered preventive wearing of Polish inserts "Piocal" for 8-15 hours per day. With beginning of pregnancy 5-7 hours per day. Simultaneously before pregnancy administered is "Dienay" in dose 1 capsule during 3 days. After that, 2 capsules 3 more days and on the following days in dose 2 capsules 2 times per day, course duration being 3 weeks. After 7-10 day break, administered is "Neurostrim" in dose 2 capsules in the morning and 1 capsule in the evening 30 minutes before meal with course 3-4 weeks. During pregnancy additionally administered is "Lohelan" - 20-30 minutes before meal, In dose one fourth of glass 2 times per day, with course of treatment 20 days, 2-3 courses during pregnancy, and "MIGI" - 1 tablespoon without dilution 3 times per day for 15 days, 1-2 courses for entire term of pregnancy.

Cell and cell extract introduction for rejuvenation

Cell and cell extract introduction for rejuvenation

Invention refers to cosmetology and dermatology, and represents a composition for cell and skin tissue health improvement containing i) a recovered water-soluble roe fraction characterised by the content of matrix ribonucleic acid and protein in the amount 100-380 mg/ml; and ii) a lipid component from the source different from that of said roe.

Method of treating osteoarthritis

Invention refers to medicine, namely to arthrology and lymphology, and can be used for treating osteoarthritis. That is ensured by lymphotropic para-articular interstitial injections of the preparations Cycloferon and Alflutop in a single dose. The treatment is continued till elimination of pain syndrome manifestations.

Method of treating disseminated renal carcinoma

Invention concerns medicine, particularly oncology, and can be applied in treating disseminated renal carcinoma (DRC). A method consists in the preliminary analysis of patient's peripheral blood for absolute concentration of CD4+CD25+Foxp3Treg phenotype cells in mm3. If the value is higher than 100 cells/mm, the patient is prescribed with Ronkoleukin combined with Cyclophosphamide for three weeks with Cyclophosphamide administered in amount 200 mg intramuscularly three times a week every second day, while Ronkoleukin - three times a week in combination with Cyclophosphamide in amount 1 mg intravenously drop-by-drop for two hours, after dissolved in 400 ml of physiologic saline or inhaled in the same dosage, after dissolved in 8-10 ml of physiologic saline. Also, for three weeks, Neovastat is introduced by 30 ml two times a day orally daily. Said therapeutic course is followed with blood analysis for absolute concentration of CD4+CD25+Foxp3Treg phenotype cells every 5 weeks, and if observing the value exceeding 100 cells/mm3, treatment is continued by the suggested regimen same scheme, and the value below 100 cells/mm3 requires the case follow-up.

New compositions of fenofibrate and related methods of treating

New compositions of fenofibrate and related methods of treating

Invention refers to medicine and pharmacology, namely to liquid compositions for treating hyperlipidemia, containing fenofibrate dissolved in an excipient which contains omega-3 fatty acid ether and ethanol, and optionally, a surface-active substance. Besides there is disclosed a method for improving fenofibrate solubility in omega-3 fatty acid ether that involves addition of ethanol to said omega-3 fatty acid ether, and also a methods of treating a patient suffering hyperlipidemia. Said improvement of fenofibrate solubility is ensured by the fact that the liquid compositions additionally contain ethanol in minimum amount 10 wt % of the composition weight. Besides a surface-active substance is optionally added to the liquid compositions specified above to ensure better digestion and reduced food intake effect.

Drug for treating stomach cancer

Invention refers to preparation of a plant drug for treating stomach cancer. The drug for treating stomach cancer contains cod-liver oil, badger fat, plant seed blood chosen from the group: pomegranate, hot pepper, fennel and activated coal in the following ratio, wt %: cod-liver oil 28; badger fat 28; seed blood 42; activated coal the rest.

Novel pharmaceutical statin compositions and treatment methods connected with it

Novel pharmaceutical statin compositions and treatment methods connected with it

Pharmaceutical compositions include divalent, namely calcium, magnesium or zinc salt, of pravastatin or fluvastatin and omega-3 fat, for prevention, reduction or treatment of increased cholesterol levels, atherosclerosis, hyperlipidemia, cardio-vascular disorders and diseases, coronary heart disease and/or cerebrovascular disease.

Composition and method of application in cartilage involvements

Method for correction of cartilage pathologies in animals involves introduction to an animal of a cartilage pathology reducing, effective and nontoxic amount of a combination of at least one sulphur amino acid and manganese where at least one sulphur amino acid is chosen from the group consisting of D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, Dl-cysteine, D-cystine, L-cystine, Dl-cystine, alpha-hydroxy-analogue of methionine, beta- hydroxy-analogue of methionine, manganese methionine and mixtures thereof. The same combination of at least one sulphur amino acid and manganese is introduced to an animal for prevention of cartilage degradation, and also added to the composition and set applicable in correction of cartilage pathologies, reduction of cartilage pathologies or prevention of cartilage degradation in animals.

Method of remission management with regard to opportunstic infections in hiv patients

Method of remission management with regard to opportunstic infections in hiv patients

Substance of the invention consists in introduction of a complex of biologically active additives and plant preparation factors separately, sequentially between meals. Said biologically active additives include propolis in the form of 20% propolis butter, bear fat, seal fat and eicosavitol. The plant preparations are aspen bark tincture, arrowwood and cranberry water, vitamin herb tea combined with iodine-active and farina. Therapeutic course of the biologically active additives and plant preparations is 82-84 days.

Method for treating early knee osteoarthrosis

Method for treating early knee osteoarthrosis

For treating early knee osteoarthrosis, the patient's blood plasma and daily urine are analysed. Treatment is prescribed for those patients, who showed lowered hexose/hexuronic acids relation, increased sulphates/hexuronic acids relation in blood plasma, increased content of sialic acids in blood serum and daily urine, as well as increased content of hexuronic acids and hydroxyproline in daily urine. These patients take Teraflex orally 2 capsules twice a day within 3 weeks, then 1 capsule twice a day during 6 months. It is combined with intra-articular introduction of Fermatron, or Sinvisk, or Ostenil, or Alflutop in effective dose 3 times every 5 days.

Fish protein hydrolyzate

Fish protein hydrolyzate

There is offered application of the substance representing enzyme-processed fish protein hydrolyzate able to inhibit activity of acyl-CoA cholesterole acyltransferase and to intensify mitochondrial β-oxidation for making a pharmaceutical or food composition applied for treatment and/or prevention of hepatic adipose degeneration in animals, for treatment and/or prevention of hypercholesterolemia and for treatment and/or prevention of hyperhomocysteinemia, and also for treatment and/or prevention of atherosclerosis, coronary heart disease, stenosis, thrombosis, myocardial infarction and stroke in an animal. There is offered method for making enzyme-processed fish protein hydrolyzate able to inhibit activity of acyl-CoA cholesterole acyltransferase, to reduce triglyceride concentration in liver, to reduce homocysteine concentration in plasma and/or to intensify mitochondrial β-oxidation. The preferential embodiment of the invention concerns FPH application as an antiatherogenic and cardioprotective agent presented either as a pharmaceutical agent, or as a functional food.

Antithrombotic composition on basis of heparin for peroral application

Antithrombotic composition on basis of heparin for peroral application

Invention concerns pharmacology and medicine and concerns an antithrombotic composition on a basis of heparin and its applications in quality of anticoagulant, antiplatelet, fibrinolitic, fibrindepolarising agent at peroral intake. The composition contains high-molecular heparin and in addition fish oil Eikonol in the form of its 25-45% solution in alimentary vegetable oil in quantity equal to 1 ml of Eikonol on 80-120 ME of antithrombic activity of high-molecular heparin. At use of liquid high-molecular heparin, parity Eikonol : heparin peer 1:0.018-0.022 (according to the volume) is used. At use of dry high-molecular heparina, a parity of 0.8-1.2 wt on 1 tot is used. For antithrombotic composition, refined alimentary oil, for example corn is used.

Preventive-medicinal antimutagenic medication and method of its application

Claimed is application of "Eicosavitol", preparation, obtained by special processing of internal fat of delicatessen kinds of the Ob basin fish (whitefish, Siberian white salmon, sturgeon) as antimutagenic medication. "Eicosavitol" is unique in composition, contains up to 15% of irreplaceable higher fatty acids of "Omega 3" family, vitamins A, D, E. Also claimed is method of preventive-medicinal influence. It is shown that medication stimulates DNA synthesis 2-4 times relative to control level and causes change of DNA conformation, which appears in separation of polynucleotide chains (DNA "melting") and hyperchromism.

Preparation "darman" for treatment of gastric ulcer disease

Invention relates to chemical-pharmaceutical industry, namely to creation of medications for treatment of gastric ulcer disease of various localisation. Medication for treatment of gastric ulcer disease contains sea oil (sea fish oil), sap of plant seeds, selected from group: pomegranate, chilly, dill and activated coal with following component ratio, wt %: sea oil (sea fish oil) - 56; sap of plant seeds, selected from group: pomegranate, chilly, dill - 42; activated coal - the remaining part.

Treatment method of early stages of hip joint osteoarthrosis

Treatment method of early stages of hip joint osteoarthrosis

Invention concerns medicine, orthopedy, and can be used for treatment of early stages of an osteoarthrosis of a hip joint. For this purpose spend ultrasonic scanning over area of a sick joint is spent. Degenerate cysts are determined. Then the skin is anaesthetised with 0.5% solution of Novocainum in amount of 4.0-5.0 ml. Under the ultrasound control the needle is entered for an injection into depth before contact to a site fibro-cartilage joint labiums. Then a chondroprotector is entered into a degenerate cyst through this needle. Introduction of the chondroprotector is carried out 3-5 times in 2-3 days.

Method for treatment of posttraumatic osteoarthrosis deformans

Method for treatment of posttraumatic osteoarthrosis deformans

Genera common radon baths are performed with concentration of radon 0.2 kBq/l, exposition of 15 minutes, temperature of 36 °C for 10 sessions carried out every other day. In the days free of radon therapy, pelotherapy is performed at 20-24 C°, exposition is 20 minutes, the course consists of 10 sessions every other day. Low-frequency magnetotherapy with variable magnetic field the frequency of which is 50 Hz, magnetic induction - 25-30 mT is carried out each day within 15 minutes during 20 days. Alpha applicator with daughter products of radon with specific activity 37 Bq/cm2, exposition - 120 minutes is locally applied during 20 days. Intra-articular introduction of "Alphlutop" per 2 ml is done each three day, the course comprises 5 sessions.

Composition of alimentary additive, suitable for improvement of iron absorption

Composition of alimentary additive, suitable for improvement of iron absorption

Agent includes cartilage or chondroitin sulfate and alible zinc.

Bioactive complex

Bioactive complex "arctic+" and method of treatment of oncology diseases

Bioactive complex with anti-tumor, antidepressant and wound-healing activities is invented; it contains the secretion of renal tubules of spawning male of thornback - 640-690 mg of solid, and secretion of gills of Atlantic salmon of activated by symbiotic larvae of pearl oyster life cycle - 320-480 mg of solid per 1000 mL of finished product, and five-year-old brandy - the rest. The invented method for treatment of oncology diseases consists in oral administration of the bioactive complex 10-30 mL on an empty stomach 10-40 min before meal not less than twice a day for 2-8 weeks. The invented method for treatment of depressive disorders consists in oral administration of bioactive complex 10-30 mL on an empty stomach 10-40 min before meal not less than twice a day for 2-8 weeks.

Therapy and prophylaxis method for preventing blepharoconjunctivitis recurrence related to demodicosis

Method involves instilling derinate solution into eye 30 min before treating eyelid edges with acaricide preparation during the whole 3 weeks long treatment course. To prevent disease recurrence, the derinate instillation course is repeated in spring and autumn during 10-14 days after having finished treatment course.

Method for treating atherosclerosis

Method for treating atherosclerosis

The innovation in question deals with carrying out combined intravenous and external laserotherapy in combination with complex medicinal impact upon the body. Additionally, it is important to fulfill monitor intestinal emptying, daily, about 6-8 procedures/course. External laserotherapy should be carried out onto corporal and auricular points. Medicinal therapy deals with introducing T-activin immunomodulators intramuscularly at the dosage of 100 mcg/d and Halavit at the dosage of 100 mg/d, about 10-20 procedures/course. It is important to apply Aciclovir at the dosage of 1 g/d, therapy course corresponds to 14. The intake of Eiconol in capsules at the dosage of 6-9/d, copper derivatives of chlorophyll at the dosage of 0.1g/d and food additive sodium alginate at the dosage of 4 g/d should be carried out during the whole therapy course. Intravenous and external laserotherapy should be fulfilled at about 8-10 procedures/course. The innovation normalizes cellular and humoral immunity, prolongs the aftereffects of therapy conducted and decreases the number of its complications.

Method for production of apyrogenic immunomodulating agent

Method for production of apyrogenic immunomodulating agent

Claimed apyrogenic immunomodulating agent represents sodium salt of native low molecular deoxyribonucleic acid. Method for production of said agent includes defatting, grinding and homogenizing of salmon or sturgeon fish roe in citrate-salt aqueous solution at 12000 rpm. Homogenate is centrifuged in settling centrifuge at 3500 rpm under cooling; supernatant is removed; substrate is homogenized again for 3-4 times with addition of calculated amount of citrate-salt solution to form air-and-fat foam followed decantation thereof. Further purified homogenate is incubated in presence of 3-6 % detergent. Saturated sodium chloride solution is added into reaction mass while continuous agitation at elevated temperature. Reaction mass is cooled to 10°C, treated with ultrasound in bath with piezoceramic emitters having vibration frequency of 21.7-23 kHz and moment of resistance at least 9 mum at generator power of 1.5-3 kW. Further liquid phase is separated with sorbent, sorbent is eluted with permeate, eluate, combined with liquid phase is microfiltered, concentrated, sodium deoxyribonucleate is deposited with alcohol, centrifuged, separated from liquid phase, dried under aseptic conditions for 4-6 h at 40-60°C. Amorphous white power containing 95-105.5 % of main substance and nativity above 2.3 is dissolved in 0.9-0.95 % sodium chloride aqueous solution in determined concentrations and poured under sterile conditions in therapeutic dosages at pH 8.0 to produce target immunomodulating agent for intravenous or intramuscular administering.

Method for isolating dna sodium salt from animal tissue

Invention relates to a method for preparing biologically active substances. Proposed method for isolating DNA sodium salt from animal tissues involves defrosting raw at temperature +25 ± 5° in aseptic condition and extraction is carried out in reactor in 10% sodium chloride solution taken in the amount 3 l of solution per 1.5 ± 0.1 kg of raw at temperature +95-98°C at stirring and constant liquid volume. Filtration of extract is carried out at rate 0.5 l/min, not above, and precipitate containing DNA sodium salt is prepared by addition ethyl alcohol to extract in the amount 4 l per 1 kg of raw. Mixture is stirred and remained at temperature +2-10°C for 20-25 h. Supernatant liquid is decanted and precipitate is separated by centrifugation and dried. Method provides reducing labor intensity, simplifying technology and enhancing yield of the end product.

Method for preventing and suppressing mammary gland carcinoma growth under experimental conditions

Method for preventing and suppressing mammary gland carcinoma growth under experimental conditions

Method involves introducing bio-organic animal preparation in advance during 4 days at daily intramuscular dose of 0.3 per 100 g of animal mass, before introducing cancerogenic agent. Then, the cancerogenic agent injections are started and continued during 30 days.

Method for treating mammary gland carcinoma in experiment

Method for treating mammary gland carcinoma in experiment

Method involves carrying out combined chemotherapy according to AC-scheme of adriamycin+cyclophosphane. Bioorganic preparation of animal origin is intramuscularly introduced in parallel to chemotherapy to a group of rats at a dose of 0.3 ml/100 g of body weight every day during 30 days.

Method for complex therapy of focal infections in sea mammalians

One should inject medicinal preparation for animals simultaneously externally and internally, moreover, as medicinal preparation it is necessary to apply antiseptic preparation based upon technical fish oil. The preparation mentioned should be applied twice or thrice daily onto animal's skin. At first, affected part of skin should be washed with preparation's solution at concentration of 1:4 - 1:5, correspondingly, antiseptic preparation : solvent with pulsing stream at alternating increased and decreased pressure. Then it is necessary to lubricate with the preparation in its pure form or with its solution at concentration being 1:1 up to 1:3, correspondingly, antiseptic preparation : solvent. Simultaneously, the preparation should be given for oral intake as a dietary constituent at 5 ml/100 kg body weight in animals. The innovation provides inhibition of microflora, the decrease of bacterial seeding of a wound and shortens therapy terms.

Method for treating patients with urogenital herpes-viral infection in combination with chlamydiosis

Method for treating patients with urogenital herpes-viral infection in combination with chlamydiosis

On establishing the diagnosis at the first stage of therapy it is necessary to prescribe derinate as 1.5%-solution per 5.0 ml intramuscularly 5 times every 48 h followed by magneto-infrared-laser impact: wave length being 0.85-0.95 mcm, impulse frequency being 50 Hz, power of light diodes radiation being 50 mW, magnetic induction corresponds to about 20-80 mTl, dosage of energetic impact ranges 0.8-1.07 J/sq. cm. Total time for procedure - 10 min. One should affect the area of thymus gland for 2 min, spleen - 2 min, inguinal lymph nodes - per 2 min, lumbosacral - 2 min. Therapy course consists of 10 daily procedures. The innovation enables to shorten therapy terms, improve quality of life in patients with urogenital herpes-viral infection in combination with chlamydiosis and increase the number of medicinal preparations for treating the above-mentioned combination of infections.

Method for prophylaxis of pregnancy gestosis

Invention relates to a method for prophylaxis of the pregnancy gestosis. Method involves administration of aspiring beginning from the second trimester of pregnancy and additional administration of the preparation "Omeganol" in the dose 2 capsules, 3 times per a day for 1 month. Then 2 months later the course of administration of the preparation "Omeganol" is repeated. Method provides improving circulation in the system mother-placenta-fetus and anticoagulant and fibrinolytic effects that results to decreasing hypercoagulation that accompanies gestosis in pregnancy.

Method for treating for painless myocardial ischemia disease

Method involves administering Eucanol at a daily dose of 3-4 g and Ispradin at a daily dose of 1.2-1.3 mg twice a day. Eucanol is taken during a meal and Ispradin is taken 30-40 min before meals.

Method for cosmetic rehabilitation of skin tissues in post-operating and other posttraumatic conditions (variants)

Invention relates to medicative and cosmetic agents, and uses of biologically active substances based on natural biological complexes. Claimed method includes application of Mirralgin balm having analgesic, anti-inflammation and resolving action, Reventon balm, having vessel restorative action, for edema reducing and microcirculation improving. In process of blepharoplastic eye boundary bandage microemulsion having recovery and animative action on eaves skin is applied, and in process of facelifting cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied. Mirralgin balm and Reventon balm treatment is carried out sequentially or alternatively. In another embodiment after skin cleaning and treatment of damaged zone with anti-septic agent Bacteriophage gel, which disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process is applied, then posttraumatic zone is treated with cleaning milk, toned up with tonic lotion and cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied.

Method for extraction and purification of cartilage-type proteoglycan (variants)

Method for extraction and purification of cartilage-type proteoglycan (variants)

Claimed method includes utilization of acetic acid as cartilage eluating solvent. According the second embodiment method includes additional filtration of solution containing crude proteoglycan to remove precipitate from said solution. Then filtered solution is centrifuged, ethanol saturated with sodium chloride is added to obtained supernatant, and supernatant is centrifuged to concentrate abovementioned crude proteoglycan in precipitate. According the third embodiment method additionally includes dissolution of said precipitate with acetic acid. Proteoglycan obtained by method of present invention may bi administered perorally.

Method for production of heterogeneous deoxyribonucleic acid (dna) sodium salt

Claimed method for production of heterogeneous deoxyribonucleic acid (DNA) sodium salt from animal male gonads and/or sperm thereof includes grinding and homogenization of starting raw materials in detergent solution, solution treatment at elevated temperature with simultaneous stirring, liquid phase separation by filtering and product precipitation with alcohol. Homogenization is carried out in 1-4 % sodium dodecyl sulfate solution in distilled water at 35-60°C with continuous stirring for 1.5-4 h followed by addition of coagulation agent, namely alkali or earth alkali metal permanganate to produce coagulation agent concentration in solution of 0.0005-0.03 M. Obtained solution is stirred at 35-60°C for 25-90 min, than ionic force is increased up to 1-3 M, solution is heated up to 60-62°C and stirred at abovementioned temperature for 1-3 h. Further contaminant precipitate obtained in coagulation process is separated by filtration thought filter having pore size from 1 to 25 mum. Filtered solution of non-fragmented (high molecular) DNA is cooled to 0-20°C, alcohol is added to obtain finished concentration of 27043.5 vol. %, Then obtained solution is agitated and deposited with alcohol preparation is filtered and separated, washed with 96 % ethanol and stored under ethanol. Obtained DNA preparation is dissolved in 0.01-4.5 M NaCl aqueous solution at 50°C or less; obtained solution is passed through high pressure homogenizer under pressure up to 2000 kg/cm2, obtained fragmented DNA is treated with alcohol wherein deposited with alcohol fermented sodium DNA is centrifuged and separated. Separated precipitate is rewashed with alcohol and dried in desiccator at 50°C or less to produce powder.

Method for manufacturing protamine sulfate (salmine) out of mature salmon soft roe

Raw soft roe should be reduced, treated at certain temperature with 0.2%-acetic acid solution, dehydrated with alcohol, dried to obtain granules, granules should be extracted with sulfuric acid solution at three stages, proteins should be precipitated out of extract by adding triple volume of ethanol, residue should be dissolved, solution should be treated with barium hydroxide up to pH being 7.0-7.5 followed by addition of ammonia up to pH being 10.5-11.5 to separate the residue due to decanting and centrifuging. Solution obtained after decanting and centrifugate should be treated with kieselguhr at heating up to 80 C and filtered upon a Nutch filter, one should apply filtrate through cationite in "H+"-form, eluate should be concentrated due to vacuum evaporation or by applying baromembranous technique, then one should precipitate the product out of eluate with triple volume of alcohol due to a 5-fold reprecipitation along with centrifuging and drying the residue to remove residual moisture and dry ready-to-use product at 55-65 C for 24 h. The present innovation enables to increase the degree of purification of protamine sulfate due to purifying against accompanying foreign proteins.

Another patent 2513875.

© 2013-2014 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.